Stockreport

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) –– Results were featured as late-breakers at the 2025 AAAAI Annual Meeting –– Xolair is the [Read more]